Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Ken Griffin’s Citadel bets £300mn against drugmaker GSK
Economy

Ken Griffin’s Citadel bets £300mn against drugmaker GSK

Last updated: February 14, 2025 9:56 am
Share
Ken Griffin’s Citadel bets £300mn against drugmaker GSK
SHARE

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Hedge fund Citadel has made a bold £305 million bet against drugmaker GSK, marking the largest short position against the company in over a decade. Billionaire Ken Griffin’s hedge fund revealed its net short position on Tuesday, amounting to 0.51 per cent of the company’s stock, as per data from the Financial Conduct Authority analyzed by provider Breakout Point.

This move by Citadel comes amidst GSK’s recent surge in share price, with a notable 11% increase in the last month. The pharmaceutical giant raised its long-term sales forecast and initiated a rare £2 billion stock buyback earlier this month. GSK’s positive earnings report, driven by strong sales of HIV and cancer drugs, has contributed to the stock’s upward trajectory.

However, despite these recent developments, GSK has struggled to outperform its competitors in the pharmaceutical sector. The company faces challenges in exciting investors about its pipeline of new medicines and vaccines, crucial for replacing its HIV drugs as they approach a patent cliff in the coming years. Over the past five years, GSK shares have declined by 15%, contrasting with the 45% rise in the S&P 500 pharmaceutical index.

GSK’s CEO, Emma Walmsley, has faced scrutiny, notably from activist investor Elliott Management, questioning her leadership due to her lack of scientific background. The company also encountered pressure to explore takeover offers for its consumer health business Haleon, which was eventually spun off.

Analysts have expressed mixed views on GSK’s future prospects. While some view the fourth-quarter earnings and 2025 guidance positively, concerns linger about the company’s buyback strategy amidst the impending HIV patent cliff. GSK’s shares suffered a setback in 2022 due to Zantac lawsuits, although a settlement was reached in October last year. The company also faced setbacks with key products like cancer drug Blenrep and the Arexvy vaccine for RSV.

See also  Best American Express credit cards for 2025

Citadel, known as the world’s top-performing hedge fund, manages a significant portfolio across various assets including equities. With $65 billion in investor capital, Citadel’s strategic bets have positioned it as a formidable player in the financial markets. GSK’s shares closed lower by 0.5% at 1,438p at the end of Friday trading in London.

Both Citadel and GSK have refrained from commenting on these developments, adhering to their policies of not disclosing individual positions or shareholders.

TAGGED:300mnbetsCitadeldrugmakerGriffinsGSKKen
Share This Article
Twitter Email Copy Link Print
Previous Article Slow Travel Is More Sustainable Travel Slow Travel Is More Sustainable Travel
Next Article Don’t buy Brad Lander crime pander — he’s a cynical leftist lying to win the mayor’s office Don’t buy Brad Lander crime pander — he’s a cynical leftist lying to win the mayor’s office
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Fires in the Amazon forest may melt sea ice in Antarctica

The impact of soot from forest fires in the Amazon on the melting of ice…

April 18, 2025

The 12 Best Garden Weddings in Vogue

Garden weddings are a dream for many couples, offering a perfect blend of human art…

May 1, 2025

A New Route for Half Marathon Runners

The New York City Half Marathon, scheduled for this Sunday, will take on a new…

March 14, 2025

President Trump Turns the Tables on Kristen Welker When Questioned About Possible Recession (VIDEO) |

In a recent interview at Mar-a-Lago, President Trump engaged in a dialogue with Kristen Welker,…

May 3, 2025

November 2, Truman defeats Dewey

Today is Saturday, Nov. 2, the 307th day of 2024. There are 59 days left…

November 2, 2024

You Might Also Like

BTIG Remains Positive on NextEra Energy (NEE), Highlighting its “Premier Generation Development Platform”
Economy

BTIG Remains Positive on NextEra Energy (NEE), Highlighting its “Premier Generation Development Platform”

October 31, 2025
3 Must-Buy Stocks Fueling the Data Center Surge
Economy

3 Must-Buy Stocks Fueling the Data Center Surge

October 31, 2025
Shake Shack returns to profit in Q3 2025
Economy

Shake Shack returns to profit in Q3 2025

October 31, 2025
Fresnillo signs agreement to acquire Probe Gold for 8m
Economy

Fresnillo signs agreement to acquire Probe Gold for $558m

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?